Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 66

Results For "IDA"

2192 News Found

Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components
News | November 13, 2025

Biotronik selects Syensqo’s Eviva Polysulfone for pacemaker header components

The high-performance polymer’s transparency and biocompatibility support precise implantation and long-term reliability


JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
News | November 12, 2025

JB Pharma Q2 PAT up 19 % at Rs. 208 Cr

Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore


Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics
R&D | November 12, 2025

Revvity launch new somatic cancer reference standards to to boost precision in oncology diagnostics

The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line


Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia
Clinical Trials | November 11, 2025

Teva’s AUSTEDO and AUSTEDO XR demonstrate real-world improvement in patients with tardive dyskinesia

The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life


Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
News | November 10, 2025

Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr

Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives


Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
Clinical Trials | November 10, 2025

Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer

Relmada expects to initiate its Phase 3 program in the first half of 2026


Philips reiterates FY25 outlook following steady Q3 performance
News | November 07, 2025

Philips reiterates FY25 outlook following steady Q3 performance

Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year